Industry Roundup: FTC, FDA Enforcement, Soft Chew, Bulu Mining
This article was originally published in The Tan Sheet
FTC clear on gray area of supplement claims; Soft Chew adds to GNC offerings; Aldrin in Re Muscle Health’s orbit; and more news in brief.
You may also be interested in...
Consent decree closes Pick and Pay more than four years after FDA found GMP and other problems; and Vitamin Shoppe will add Carlson Capital nominees to board
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.